Showing 661 - 670 of 683
Although US health care expenditures reached 17.6 percent of GDP in 2009, quality measurement in this important service sector remains limited. Studying quality changes associated with 11 years of health care for patients with diabetes, we find that the value of reduced mortality and avoided...
Persistent link: https://www.econbiz.de/10009132657
<DIV><DIV><DIV><P>The celebrated economist Zvi Griliches’s entire career can be viewed as an attempt to advance the cause of accuracy in economic measurement. His interest in the causes and consequences of technical progress led to his pathbreaking work on price hedonics, now the principal analytical technique...</p></div></div></div>
Persistent link: https://www.econbiz.de/10011156053
<DIV><DIV><P>This volume contains papers presented at a conference in May 1988 in Washington, D.C., commemorating the fiftieth anniversary of the founding of the Conference on Research in Income and Wealth (CRIW). The call for papers emphasized assessments of broad topics in economic measurement, both...</p></div></div>
Persistent link: https://www.econbiz.de/10011156056
<DIV>With the United States and other developed nations spending as much as 14 percent of their GDP on medical care, economists and policy analysts are asking what these countries are getting in return. Yet it remains frustrating and difficult to measure the productivity of the medical care service...</div>
Persistent link: https://www.econbiz.de/10011156201
In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab—brand name Yervoy—at $120,000 for a course of therapy. The drug was associated with an incremental increase in life expectancy of four months. Drugs like ipilimumab have fueled the perception that the...
Persistent link: https://www.econbiz.de/10011156823
Drugs like bevacizumab ($50,000 per treatment episode) and ipilimumab ($120,000 per episode) have fueled the perception that the launch prices of anticancer drugs are increasing over time. Using an original dataset of 58 anticancer drugs approved between 1995 and 2013, we find that launch...
Persistent link: https://www.econbiz.de/10011123634
To overcome the problem of insufficient research and development (R&D) on vaccines for diseases concentrated in low-income countries, sponsors could commit to purchase viable vaccines if and when they are developed. One or more sponsors would commit to a minimum price that would be paid per...
Persistent link: https://www.econbiz.de/10011071268
Persistent link: https://www.econbiz.de/10005388518
Persistent link: https://www.econbiz.de/10005280986
In this essay I provide a wide-ranging overview of recent research linking medical treatments to productivity and ability to function. The studies that examine how do illness and medical treatments affect absenteeism, at-work productivity (“presenteeism”) and ability to function vary in the...
Persistent link: https://www.econbiz.de/10005549229